Nektar Therapeutics, a leading biotechnology company specializing in treatments for auto-immune disorders, has recently secured a substantial private placement financing agreement with TCGX, a reputable institutional accredited investor. This deal will result in a capital raise of $30 million for Nektar.
The financing arrangement entails the sale of 25 million shares of Nektar’s common stock in the form of a pre-funded warrant, priced at $1.20 per share. This represents an impressive 80% premium compared to the company’s 30-day volume-weighted average price. The pre-funded warrant includes an exercise price of $0.0001 per share and has no expiration date.
The closing of this significant deal is anticipated to take place on or before March 6, 2024, subject to customary closing conditions. Following the transaction’s completion, Nektar intends to file a registration statement for the underlying Common Stock within 90 days.
NKTR Stock Surges 25.64% on March 4, 2024: Trading Above 200-Day Moving Average
On March 4, 2024, NKTR stock showed strong performance as it traded in the middle of its 52-week range and above its 200-day simple moving average. The stock opened at $0.96, which was $0.18 higher than its previous close, indicating a positive start to the trading day.
Throughout the day, NKTR shares saw a significant increase in price, rising by $0.20 since the market last closed. This represented a 25.64% increase in the stock price, reflecting strong momentum and investor interest in the company.
NKTR Stock Shows Positive Signs with Growth in Net Income and EPS Despite Revenue Decrease
On March 4, 2024, NKTR stock showed some positive signs despite a decrease in total revenue compared to the previous year. The company reported a total revenue of $92.06 million for the past year, which represented a 9.67% decrease from the previous year. However, there was a 17.78% increase in total revenue compared to the previous quarter, with a total revenue of $24.14 million in Q3.
In terms of net income, NKTR reported a net loss of $368.20 million for the past year, which was an improvement of 29.71% compared to the previous year. In Q3, the company reported a net loss of $45.84 million, representing a 10.34% increase compared to the previous quarter.
Earnings per share (EPS) also showed positive growth for NKTR stock. The company reported an EPS of -$1.97 for the past year, which was a 31.15% increase compared to the previous year. In Q3, the company reported an EPS of -$0.24, representing a 10.72% increase compared to the previous quarter.
Overall, despite the decrease in total revenue compared to the previous year, NKTR stock showed positive growth in net income and EPS. Investors may view these improvements as a positive sign for the company’s financial performance and potential for future growth.
